Analysts have clear opinions on PDLI.
There are 1 analyst offering 12 month price targets for PDL BioPharma in the last 3 months. The average price target is $3.00 with a high forecast of $3.00 and a low forecast of $3.00. The average price target represents a -9.64% decrease from the last price of $3.32.
PDL BioPharma, Inc. (PDLI) is followed by 1 analysts on the street.
Phil Nadeau from Cowen & Co. rates it a Hold with a target of $3.00.
Similarly, null null of null null a null with a target of null.
The consensus on the street is Hold.
What does PDL BioPharma, Inc.(PDLI) do ?
PDL BioPharma, Inc. produces and markets biopharmaceutical products. It operates through the following segments: Income Generating Assets, Pharmaceutical, and Medical Devices. The Income Generating Assets segment consists of revenues derived from notes and other long-term receivables, royalty rights-at fair value, equity investments, and royalties from issued patents in the United States and elsewhere. The Pharmaceutical segment covers revenues from branded prescription medicine products being sold under the name Tekturna and Tekturna HCT in the United States, and Rasilez and Rasilez HCT for the rest of the world. The Medical Devices segment handles revenues from the LENSAR Laser System sales. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Incline Village, NV.
PDL BioPharma, Inc. (PDLI) Insider Trades
Looking for stocks just like PDLI?
Based on Wall Street analyst research, several stocks are similar to PDLI
– BIIB [Info can be found here: https://www.nasdaq.com/market-activity/stocks/BIIB ]
– RHHBY [Info can be found here: https://www.nasdaq.com/market-activity/stocks/RHHBY ]
– BMY [Info can be found here: https://www.nasdaq.com/market-activity/stocks/BMY ]